Everolimus
-
Giredestrant Improves Progression-Free Survival in ER-Positive Advanced Breast Cancer: Roche’s Phase III evERA Trial
Roche’s Phase III evERA trial showed promising results for giredestrant plus everolimus in ER-positive, HER2-negative advanced breast cancer after CDK4/6 inhibitor therapy. The combination significantly improved progression-free survival (PFS) compared to standard endocrine therapy plus everolimus. The PFS risk reduction was 44% in ITT and 62% in ESR1-mutated patients. While overall survival data is still maturing, a positive trend was observed. Giredestrant + everolimus could become a new standard of care.
